Status:
UNKNOWN
Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Dermatomyositis, Adult Type
Interstitial Lung Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
We conduct this study to investigate the efficacy of triple therapy (high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor) compared with dual-therapy regimens (high-dose glucocorticoid...
Eligibility Criteria
Inclusion
- Adult patients meet the diagnostic criteria for dermatomyositis of Bohan and Peter
- Anti-MDA5 Antibody-positive
Exclusion
- Complicated with other connective tissue diseases
- Complicated with cardiovascular and respiratory disease caused by other reasons
- Interstitial lung disease caused by environment and drugs
- Patients with key research missing data or without informed consent
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05375435
Start Date
January 1 2022
End Date
December 31 2024
Last Update
May 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China, 210029